Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Colorcon
Harvard Business School
Johnson and Johnson
Moodys

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VANDETANIB

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for VANDETANIB

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00066313 ↗ ZD6474 in Treating Patients With Small Cell Lung Cancer Completed Genzyme, a Sanofi Company Phase 2 2003-05-01 RATIONALE: ZD6474 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ZD6474 may also stop the growth of small cell lung cancer by blocking blood flow to the tumor. PURPOSE: This randomized phase II trial is studying how well ZD6474 works compared to placebo in treating patients with small cell lung cancer that has responded to previous chemotherapy with or without radiation therapy.
NCT00290537 ↗ Phase II Study of ZD6474 in Advanced NSCLC Terminated AstraZeneca Phase 2 2006-01-01 The goal of this clinical research study is to learn how the drug ZD6474 affects the amount of tumor cell death in the body and the amount of blood that can be supplied to the tumor. The safety of ZD6474 alone and when given with chemotherapy will be studied. In addition, the side effects and response to this treatment will also be studied.
NCT00290537 ↗ Phase II Study of ZD6474 in Advanced NSCLC Terminated M.D. Anderson Cancer Center Phase 2 2006-01-01 The goal of this clinical research study is to learn how the drug ZD6474 affects the amount of tumor cell death in the body and the amount of blood that can be supplied to the tumor. The safety of ZD6474 alone and when given with chemotherapy will be studied. In addition, the side effects and response to this treatment will also be studied.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for VANDETANIB

Condition Name

Condition Name for VANDETANIB
Intervention Trials
Lung Cancer 10
Non Small Cell Lung Cancer 6
Prostate Cancer 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for VANDETANIB
Intervention Trials
Lung Neoplasms 21
Thyroid Neoplasms 16
Thyroid Diseases 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for VANDETANIB

Trials by Country

Trials by Country for VANDETANIB
Location Trials
United States 198
Italy 38
Canada 36
United Kingdom 28
China 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for VANDETANIB
Location Trials
Maryland 15
Texas 14
New York 11
California 10
Michigan 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for VANDETANIB

Clinical Trial Phase

Clinical Trial Phase for VANDETANIB
Clinical Trial Phase Trials
Phase 4 1
Phase 3 7
Phase 2 42
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for VANDETANIB
Clinical Trial Phase Trials
Completed 48
Terminated 21
Active, not recruiting 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for VANDETANIB

Sponsor Name

Sponsor Name for VANDETANIB
Sponsor Trials
AstraZeneca 29
Genzyme, a Sanofi Company 25
National Cancer Institute (NCI) 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for VANDETANIB
Sponsor Trials
Other 76
Industry 72
NIH 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Boehringer Ingelheim
Baxter
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.